Cyngn (CYN) said Friday that it priced a follow-on offering and plans to use the gross proceeds of about $20 million and cash at hand for working capital and other general corporate purposes.
Shares slumped 74% following a surge in intraday trading volume to over 23.3 million from a daily average of about 670,000.
Galectin Therapeutics (GALT) said Friday its trial evaluating belapectin in cirrhotic portal hypertension patients showed a 48.9% reduction in varices in the per-protocol population for the 2 mg/kg dose group. But, in the intent-to-treat population, the composite endpoint "did not reach statistical significance" even though the incidence of varices showed a 43.2% reduction.
Shares plunged 53% as intraday trading volume soared to over 7.7 million from the stock's daily average of about 294,000.
FingerMotion's (FNGR) shares sank 41% amid heavy trading after the technology company said it agreed with investors to raise $5 million in gross proceeds from the sale of common stock and warrants in a registered direct offering.
More than 3.2 million shares traded compared with a daily average of roughly 182,000.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。